Skip to content

#肿瘤

Today 1 items
TodayOct 16Fri
  1. biopharmadive.com49

    Belgian startup revives Galapagos CAR-T research

    Lakefront Biotherapeutics, formerly Galapagos, has sold its cell therapy programmes to Belgian startup Armed Cell Therapeutics for 8 million euros up front, with up to $230 million more in future payments. The deal covers two armed CAR-T therapies nearing human testing in non-Hodkin lymphoma and small cell lung cancer, plus three undisclosed preclinical projects. Armed Cell named Willemijn Kremer, a former Galapagos cell therapy executive, as CEO, replacing interim CEO Paul Stoffels.

    Why it matters: Revives shelved CAR-T programmes under a new company after Galapagos wound down its cell therapy research.

Oct 15Thu
  1. biopharmadive.com61

    Iambic, an AI drug discovery specialist, banks $150M in an IPO

    Iambic Therapeutics, an AI drug discovery startup, raised $150 million in an IPO, selling close to 9.4 million shares at $16 each and trading on the Nasdaq from Thursday under the ticker "IAM." The company has drawn $462 million in private funding since 2019 and will use the proceeds to advance its first drug, IAM1363, an oral tyrosine kinase inhibitor for HER2-positive solid tumors that showed anti-tumor activity and encouraging safety in a Phase 1 study, with a registrational trial possibly beginning in 2027. Behind it are IAM217, targeting KIF18A in ovarian and triple-negative breast cancers, and a CDK2/CDK4-targeting prospect, both potentially entering testing next year.

    Why it matters: The offering adds to a wave of AI drug discovery startups testing whether public investors will back the technology.

Oct 14Wed
  1. biocentury.com46

    Duracyte: Turning the patient into the bioreactor

    Duracyte, a Rice University spinout based in Houston, is developing subcutaneous implants of engineered human cells that continuously secrete biologics in the body for up to a year, with the aim of replacing repeated infusions and injections. The work has drawn roughly $120 million in non-dilutive funding. The company plans to start its first clinical trial in the first half of next year, testing an implant that produces the checkpoint inhibitor ipilimumab in patients with peritoneal cancer.

Oct 9Fri
  1. biospace.com54

    TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms

    TRexBio raised $116.7 million in its Nasdaq IPO, selling 8.3 million shares at $14 to fund TRB-061, a fusion protein in early-stage development for atopic dermatitis with a Phase 1b topline readout expected mid-2027. Retension Pharmaceuticals raised $45 million at $12 per share to advance RTN-001, a PDE-5 blocker for hypertension, through Phase 2b and into Phase 3. City Therapeutics expects about $158.3 million and Iambic Therapeutics about $135 million from upcoming offerings.

    Why it matters: Four biotech IPOs in one week signal a reopening of the public markets for drug developers.

  2. biospace.com58

    Merck barred from making subcutaneous Keytruda in 8 European countries

    A Dutch court has barred Merck from producing, importing, stocking or selling Keytruda SC, the subcutaneous formulation of Keytruda, in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands, after finding it infringes a Halozyme Therapeutics patent covering MDASE technology. The decision follows a German preliminary injunction in December, and Merck's appeal of that ruling has a hearing expected next month. Subcutaneous Keytruda brought in $463 million of the franchise's $8.4 billion in second-quarter sales, and a key patent expires in 2028.

    Why it matters: Patent rulings now block subcutaneous Keytruda in key European markets, affecting Merck's strategy ahead of the 2028 patent expiry.

Oct 8Thu
  1. biopharmadive.com40

    Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial

    A Netherlands court blocked sales of Merck's subcutaneous Keytruda Qlex in eight European countries, siding with Halozyme in a patent dispute over its under-the-skin drug delivery technology. Separately, Enliven Therapeutics reached agreement with the FDA on a late-stage trial of relcobitinib in chronic myeloid leukemia, enrolling 450 people to test superiority at spurring a major molecular response. Halozyme is also challenging Merck in a U.S. court after a win in Germany.

    Why it matters: Patent ruling blocks subcutaneous Keytruda across Europe and FDA-aligned CML trial design sharpens competition for Novartis and Merck.

  2. biopharmadive.com65

    Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate

    Caribou Biosciences, the CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, is discontinuing research, laying off staff and seeking strategic alternatives after failing to raise money to advance its allogeneic CAR-T programs. The move ends work on vispa-cel, which was ready for Phase 3 testing in lymphoma with an FDA-agreed trial design, and CB-011, in testing for multiple myeloma. The board will weigh mergers, acquisitions or other transactions, with the workforce reduction mostly done by year-end.

Oct 7Wed
  1. statnews.com53

    STAT+: Merck suffers a setback in Europe over its new Keytruda formulation

    A Dutch court ruled that Merck infringed a Halozyme Therapeutics patent covering a subcutaneous formulation of Keytruda and ordered the company to stop manufacturing and marketing that version in several European countries, including France, Italy, Sweden, Switzerland and the Netherlands. The decision is part of a widening patent dispute over the cancer treatment. Patients can still access the intravenous version, which is unaffected by the order. Merck was asked for comment.

    Why it matters: Court-ordered halt of a subcutaneous Keytruda formulation affects sales in several European markets.

  2. biospace.com40

    Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more

    Genmab and AbbVie's bispecific antibody Epkinly, approved in May 2023 for diffuse large B cell lymphoma after at least two prior systemic lines, cut risk of disease progression or death by 51% in a Phase 3 trial when combined with R-CHOP in the frontline setting. In deals, Shionogi bought IntraBio for $2 billion, Novartis committed up to $7.8 billion to Abogen Biosciences, Eli Lilly added up to $870 million with Gate Bioscience, and Sanofi and Regeneron renewed their collaboration with a $1 billion upfront. Sarepta shared Elevidys data in older Duchenne patients at the World Muscle Society meeting, with Jefferies citing upcoming readouts and an FDA decision on Amondys 45 and Vyondys 53.

  3. statnews.com62

    STAT+: Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down

    Caribou Biosciences, the Berkeley, California CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, is shutting down after failing to raise the money needed for a late-stage trial of its off-the-shelf CAR-T therapy for lymphoma. CEO Rachel Haurwitz said the company had finalized the design of a Phase 3 trial for vispa-cel, its treatment for advanced B-cell non-Hodgkin lymphoma, with the FDA over the past year, but could not fund the study. Caribou will discontinue clinical development of both of its CRISPR-based CAR-T therapies.

Oct 5Mon
  1. biospace.com40

    2 Massachusetts biotechs call it quits

    Boston-based Adecto Pharmaceuticals, which was developing an anti-ADAM8 monoclonal antibody for cancers unresponsive to conventional immunotherapy, ceased operations Sept. 30 after running out of financial runway, CEO Nora Minerva said on LinkedIn; she has filed a provisional patent on the lead antibody and is exploring ways to advance its development. Aviceda Therapeutics is also winding down after its nanoparticle AVD-104 missed the primary endpoint in a December-announced Phase 2b trial in geographic atrophy secondary to AMD, showing no statistical difference versus Astellas's Izervay, derailing two planned Phase 3 studies expected to start this year.

    Why it matters: Two Massachusetts biotechs are shutting down, one after a Phase 2b miss, illustrating the funding and clinical pressures on early-stage companies.

Oct 2Fri
  1. biocentury.com44

    Trio of biotechs draw nine-figure fundings: Public Equity Report

    Immix Biopharma (NASDAQ:IMIX) raised $125 million in an offering underwritten by J.P. Morgan, announced minutes after an interim readout from the Phase II NEXICART-2 trial showed its BCMA-targeted CAR-T therapy NXC-201 achieved an 89% complete response rate among 45 patients with light-chain (AL) amyloidosis. Immix plans a BLA submission next year, when final data from the study are expected. Sagimet and Pyxis Oncology also raised nine-figure sums, alongside an AstraZeneca/Summit item.

Oct 1Thu
  1. biospace.com54

    Foghorn lays off 40% of staff after Lilly collaboration ends

    Foghorn Therapeutics and Eli Lilly ended their oncology collaboration after Phase 1 data on cancer candidate FHD-909 (LY4050784) showed insufficient efficacy, halting its move into clinical development expansion and a SMARCA2 degrader program. Foghorn is cutting about 40% of its workforce, leaving roughly 65 full-time employees, and will refocus on its proprietary programs including EP300 and CBP degraders. The 2021 deal had brought $300 million upfront plus an $80 million equity investment from Lilly's Loxo Oncology, and the changes should extend Foghorn's cash runway into the second half of 2029.

    Why it matters: A terminated big-pharma oncology alliance triggers pipeline reprioritization, layoffs and a readout on the SMARCA2 synthetic lethality hypothesis.

Sep 30Wed
  1. endpoints.news41

    Merck licenses a KRAS G12D inhibitor for $400M upfront

    Merck is licensing a KRAS G12D inhibitor from entrepreneur and synthetic chemist Tao Hu for $400 million upfront. Hu previously sold a different KRAS G12D inhibitor to AstraZeneca in 2023. Terms beyond the upfront payment and next steps were not disclosed.

    Why it matters: Large upfront licensing deal for a KRAS G12D inhibitor by a repeat seller of such assets.

Sep 29Tue
  1. biospace.com52

    Summit snags $2B investment from AstraZeneca, clearing financial overhang

    AstraZeneca is investing $2 billion in Summit Therapeutics through a direct equity purchase of about 109,000 preferred shares, giving it roughly 12% of Summit's common shares at $18.36 per share, a 10% premium. The deal, expected to close within a week pending regulatory clearances, lifts Summit's cash to an estimated $2.5 billion and leaves it holding full rights to ivonescimab, the PD-1/VEGF bispecific, in its territories. The partners will also start trials pairing AstraZeneca's anti-CLDN18.2 ADC sonesitatug vedotin with ivonescimab in gastrointestinal cancers, while the FDA decides Summit's BLA for the NSCLC drug by Nov. 14.

    Why it matters: Large pharma is paying $2 billion for equity exposure to the PD-1/VEGF class without licensing ivonescimab.

  2. biopharmadive.com48

    AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push

    AstraZeneca will invest $2 billion in Summit Therapeutics by buying about 109,000 shares of convertible preferred stock, giving it roughly 12% ownership, or about 10.6% fully diluted. The companies will jointly test Summit's PD-1/VEGF drug ivonescimab with AstraZeneca medicines, starting with the ADC "Sone-Ve" in gastrointestinal tumors, and will share development costs while retaining rights to their own drugs. Ionescimab previously halved the risk of progression or death versus Keytruda in a Phase 3 lung cancer study, and the partnership may expand to further combinations.

  3. BioCentury68

    Merck turns to China-based SciBrunch for KRAS program, pays $400M up front: Deals Report

    Merck & Co. has licensed global rights to SPR2015, a preclinical KRAS G12D molecular glue inhibitor from China-based SciBrunch, paying $400 million up front. The deal follows reported failed M&A negotiations with Revolution Medicines in the $30 billion range, after that company reported in April that daraxonrasib led to a survival benefit in pancreatic cancer patients. Further deal terms for the SciBrunch agreement were not disclosed.

    Why it matters: Large upfront licensing payment by Merck for a preclinical KRAS G12D program after failed Revolution Medicines talks.

Sep 28Mon
  1. biospace.com45

    Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor

    Merck has licensed exclusive global rights to SciBrunch Therapeutics' preclinical oral KRAS G12D (ON) inhibitor SPR2015, paying $400 million upfront with milestone payments that could bring the total to $2.13 billion. The deal has closed, and Merck recorded a pre-tax charge of $400 million, about 13 cents per share, in Q3. SciBrunch expects SPR2015 to enter human trials by the end of this year. The same day, Merck and Daiichi Sankyo withdrew an accelerated approval request for ifinatamab deruxtecan in extensive-stage small cell lung cancer after the FDA said the data did not support the filing.

    Why it matters: Large licensing deal for a preclinical KRAS G12D inhibitor plus a withdrawn FDA filing shapes Merck's oncology pipeline.

Sep 21Mon
  1. STAT News65

    STAT+: Radiopharma companies merge after one receives surprise FDA rejection

    Telix Pharmaceuticals will acquire all shares of ITM Isotope Technologies Munich SE in a merger worth at least $1.65 billion, with up to $700 million more payable to ITM shareholders if ITM's lead drug meets regulatory and sales goals. The deal combines two radiopharmaceutical companies and creates a well-resourced player in a field dominated by Novartis, which launched two radioactive isotope cancer treatments in 2018 and 2022.

    Why it matters: A $1.65 billion radiopharmaceutical merger consolidates the cancer isotope delivery field shortly after an FDA rejection.

Sep 15Tue
Sep 12Sat
  1. biocentury.com54

    With deep pockets, Solstice takes next-gen CTLA-4 into neoadjuvant treatment

    Solstice Oncology has launched with a $225 million series A led by RA Capital Management, with Canaan Partners and Forbion also investing, to develop its Fc-enhanced, shorter-acting CTLA-4 antibody porustobart (HBM4003), for which it holds ex-China rights. The NewCo will test the antibody in the neoadjuvant setting to see whether giving it before surgery improves responses without toxicity delaying tumor removal. CEO Caroline Loew said the round closed at the time of the licensing deal.

    Why it matters: Large series A funds a next-generation CTLA-4 antibody moving into the neoadjuvant setting under a new company.

Sep 10Thu
  1. biocentury.com45

    BrainChild: Bringing CAR Ts directly to the brain

    BrainChild Bio Inc. of Seattle and Cambridge, Mass., raised $116 million in series A financing backed by Seattle Children's Research Institute and WRF Capital, with an undisclosed family fund leading. The company delivers CAR T cells directly into the cerebrospinal fluid rather than the bloodstream, aiming to allow repeat dosing for CNS cancers while avoiding systemic toxicities seen in other CAR T programs. Targets include B7-H3, EGFR and IL-13RA2.

    Why it matters: New financing backs a repeat-dose intrathecal CAR T approach for CNS cancers.

Sep 9Wed
  1. biocentury.com60

    GSK takes rights to Hutchmed’s KRAS-antibody conjugate: Deals Report

    GSK plc is paying $110 million up front for most global rights to HMPL-A830, a dual-targeted oncology therapy from Hutchmed China that links a KRAS inhibitor payload to an anti-EGFR antibody. HMPL-A830 is the first deal from Hutchmed's Antibody-Targeted Therapy Conjugate (ATTC) platform, which has also produced two PI3K-payload programs now in Phase I testing. The same report also covers Alteogen's delivery-tech deal with Novartis and Menarini's local in-licensing of Gan & Lee's obesity program.

    Why it matters: First licensing deal from Hutchmed's ATTC platform gives GSK most global rights to a KRAS-antibody conjugate.

Sep 3Thu
  1. fiercebiotech.com64

    GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset

    GSK has licensed Hutchmed's preclinical KRAS-EGFR antibody conjugate HMPL-A830, paying $110 million upfront in a deal worth up to $1.295 billion, excluding Mainland China, Hong Kong, Macau and Taiwan. The candidate delivers a KRAS inhibitor to EGFR-expressing tumors and is slated to enter trials later this year, initially in colorectal, pancreatic and lung cancer. Hutchmed will run Phase 1 trials, after which GSK takes over R&D and commercialization outside select Asian territories.

    Why it matters: GSK is paying up to $1.295 billion for a preclinical first-in-class KRAS-EGFR candidate, a notable early-stage oncology licensing deal.

Aug 25Tue
  1. FierceBiotech57

    McKesson strikes $2.25B deal to snap up Precision Medicine Group

    McKesson, ranked eighth on the Fortune 500 list, has agreed to acquire privately held Precision Medicine Group for $2.25 billion. The deal will fold the company into McKesson's oncology branch as part of an effort to grow its high-margin cancer and biopharma services businesses. The acquisition has not yet closed.

    Why it matters: Large pharmaceutical distributor expanding into oncology and biopharma services via a $2.25 billion acquisition.

Aug 24Mon
  1. fiercepharma.com47

    Daiichi Sankyo promotes Ken Keller to lead new commercialization unit

    Daiichi Sankyo has promoted Ken Keller, who has led its global oncology business for five years, to chief commercialization officer of a new globally integrated commercialization unit starting April 1. The restructured organization covers five regions, with internal appointments including Yuichi Yomasu in China, Markus Kosch in Europe, Marcelo Goncalves in Latin America, Kenji Shigeta in North America and Nobuo Murakami in Japan, Asia and the Pacific. The unit supports Daiichi Sankyo's plan to become a top-five oncology company by 2035 and to make five drugs available in 20 new indications by 2030.

Aug 14Fri
  1. FiercePharma48

    It's BMS vs. Celgene investors once more after US appeals court revives lawsuit

    A U.S. appeals court in Manhattan has revived a lawsuit by Celgene shareholders who accuse Bristol Myers Squibb of deliberately slowing the FDA approval of Breyanzi to avoid paying more than $6 billion under a contingent value rights deal tied to its $74 billion acquisition of Celgene in 2019. The 3-0 ruling overturned Judge Jesse Furman's 2024 dismissal and found that trustee UMB Bank can maintain the suit because BMS accepted its appointment. A related breach-of-contract case was allowed to proceed in part in December, and it is uncertain how the decision affects it.

  2. FiercePharma40

    Fierce Pharma Asia—Legend’s first profit; Taiho, Cullinan’s EGFR win; WuXi AppTec’s reprieve

    Legend Biotech posted its first profitable quarter, with $63 million in adjusted net income for the three months ended June, as interim CEO Alan Bash discussed expanding Carvykti amid competition from Johnson & Johnson's bispecifics. Taiho and Cullinan Therapeutics' EGFR inhibitor zipalertinib plus chemotherapy succeeded in a phase 3 trial in first-line EGFR exon 20-mutated non-small cell lung cancer, with FDA approval plans ahead. A federal judge granted WuXi AppTec a preliminary injunction blocking the Defense Department's 1260H Chinese military company designation, and China approved Akeso's ivonescimab with chemotherapy for first-line squamous NSCLC.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org